高级检索
当前位置: 首页 > 详情页

Optimization of solid-phase extraction and liquid chromatography-tandem mass spectrometry for simultaneous determination of capilliposide B and its active metabolite in rat urine and feces: Overcoming nonspecific binding

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Weifang Med Univ, Sch Pharm, 7166 Baotong West St, Weifang 261053, Shandong, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Sch Pharm, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China [4]Humanwell Healthcare Grp Co Ltd, Med Res Ctr, 666 Gao Xin Rd, Wuhan 430075, Hubei, Peoples R China [5]Zhejiang Univ, Dept Biomed Engn, Hangzhou 310027, Zhejiang, Peoples R China
出处:
ISSN:

关键词: Capilliposide B Nonspecific binding LC-MS/MS Excretion

摘要:
Capilliposide B, a novel oleanane triterpenoid saponin isolated from Lysimachia capillipes Hemsl, showed significant anti-tumor activities in recent studies. To characterize the excretion of Capilliposide B, a reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous determination of Capilliposide B and its active metabolite, Capilliposide A in rat urine and feces. Sample preparation using a solid-phase extraction procedure was optimized by acidification of samples at various degrees, providing extensive sample clean-up with a high extraction recovery. In addition, rat urinary samples were pretreated with CHAPS, an anti-adsorptive agent, for overcoming nonspecific analytes adsorption during sample storage and process. The method validation was conducted over the curve range of 10.0-5000 ng/ml for both analytes. The intra- and inter-day precision and accuracy of the QC samples showed <= 11.0% RSD and -10.4-12.8% relative error. The method was successfully applied to an excretion study of Capilliposide B following intravenous administration. (C) 2016 Elsevier B.V. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 3 区 分析化学 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 分析化学 3 区 药学
JCR分区:
出版当年[2014]版:
Q1 CHEMISTRY, ANALYTICAL Q2 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q2 CHEMISTRY, ANALYTICAL Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Weifang Med Univ, Sch Pharm, 7166 Baotong West St, Weifang 261053, Shandong, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:622 今日访问量:0 总访问量:452 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)